Business · Companies · 2 hrs ago

Undecimal Bio launches with $18 million to expand siRNA beyond liver disease

Undecimal Bio launches with $18 million to expand siRNA beyond liver disease

Undecimal Bio has launched with $18 million in funding.

The company aims to use siRNA beyond liver disease.

siRNA is the technology named in the company’s goal, but no further details about its plans are available here.

Undecimal is being carved out of Eleven Therapeutics.

Eleven spun off another part of its business this summer.

The launch and funding mark the next step in separating the two parts of Eleven’s business.

Sources

Related news